Impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women: Do we need a new drug?

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 11, 2008, Pages 4218-4220

  Legro, Richard S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; ORAL CONTRACEPTIVE AGENT;

BARIATRIC SURGERY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; EDITORIAL; HUMAN; HYPERANDROGENISM; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MENSTRUAL CYCLE; OBESITY; OLIGOMENORRHEA; ORAL CONTRACEPTION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

EID: 57349135982     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1994     Document Type: Editorial

References (17)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM 2006 Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295:1549-1555
2. Lee JM, Herman WH, McPheeters ML, Gurney JG 2006 An epidemiologic profile of children with diabetes in the U.S. Diabetes Care 29:420-421
3. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS 2008 The impact of metformin, oral contraceptives and lifestyle modification, on polycystic ovary syndrome in obese adolescent women in two randomized, placebocontrolled clinical trials. J Clin Endocrinol Metab 93:4299-4306
4. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403
5. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, Hamalainen H, Harkonen P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J 2006 Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368:1673-1679
6. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH 2008 The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 371:1783-1789
7. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F 2006 Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 332:1485
8. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Leppert PC, Myers ER 2007 Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 356:551-566
9. Zain MM, Jamaluddin R, Ibrahim A, Norman RJ Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril, in press
10. Ibanez L, Ferrer A, Ong K, Amin R, Dunger D, de Zegher F 2004 Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr 144:23-29
11. Bridger T, MacDonald S, Baltzer F, Rodd C 2006 Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med 160:241-246
12. Love-Osborne K, Sheeder J, Zeitler P 2008 Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr 152:817-822
13. Writing Group for the Women's Health Initiative I 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288:321-333
14. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R 2008 The effects of tibolone in older postmenopausal women. N Engl J Med 359:697-708
15. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B 2007 Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109-2122
16. Trent M, Austin SB, Rich M, Gordon CM 2005 Overweight status of adolescent girls with polycystic ovary syndrome: body mass index as mediator of quality of life. Ambul Pediatr 5:107-111
17. Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM 2008 Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet 371:923-931